Shattuck Labs (NASDAQ:STTK) Given Hold Rating at Needham & Company LLC

Shattuck Labs (NASDAQ:STTK)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports.

Other equities analysts have also issued reports about the company. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research note on Thursday. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Finally, Leerink Partners began coverage on Shattuck Labs in a report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target for the company. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Trading Down 7.5 %

NASDAQ STTK opened at $1.06 on Thursday. The company has a market capitalization of $50.37 million, a PE ratio of -0.69 and a beta of 1.66. The business’s 50-day moving average price is $1.24 and its 200 day moving average price is $1.49. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. Equities analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Atom Investors LP bought a new position in shares of Shattuck Labs during the third quarter worth about $35,000. Readystate Asset Management LP acquired a new position in shares of Shattuck Labs in the 3rd quarter worth approximately $39,000. Benjamin Edwards Inc. bought a new stake in shares of Shattuck Labs in the 3rd quarter valued at approximately $61,000. Zacks Investment Management acquired a new stake in shares of Shattuck Labs during the 4th quarter valued at approximately $25,000. Finally, Virtu Financial LLC bought a new position in Shattuck Labs during the fourth quarter worth $30,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.